5 Key Takeaways
-
1
Revolution Medicines' KRAS inhibitor daraxonrasib nearly doubled overall survival in metastatic pancreatic cancer compared to standard chemotherapy.
-
2
GSK's antibody-drug conjugate Mo-Rez showed tumor shrinkage in 62–67% of patients with chemotherapy-resistant ovarian and endometrial cancers.
-
3
Gilead's acquisition of Tubulis for $3.15 billion enhances its ADC capabilities, including TUB-040 for ovarian and lung cancers.
-
4
The FDA now publishes complete response letters in real time, increasing transparency regarding drug approval deficiencies.
-
5
Merck's partnership with Infinimmune aims to develop novel antibody therapeutics using AI-driven discovery methods.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
